TTPH
$4.62
Tetraphase Pharmaceu
$.04
.87%
TTPH
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus:  ($7.20)
Revenue:  $2.00 Mil
Thursday
Nov 7
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TTPH reports earnings?
Beat
Meet
Miss

Where is TTPH's stock price going from here?
Up
Flat
Down
Stock chart of TTPH
Analysts
Summary of analysts' recommendations for TTPH
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.
Peers
Regeneron PharmaceuticalsCelgeneInterCeptVertex PharmaceuticalsBioMarin PharmaceuticalEndo International plcJohnson & JohnsonMylanZoetisPerrigo